Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity

Arthritis Research and Therapy

Volumn 15, Issue 6, 2013, Pages

  Zizzo, Gaetano ^a   Guerrieri, Justus ^a   Dittman, Lindsay M ^a   Merrill, Joan T ^b   Cohen, Philip L ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AXL RECEPTOR; BIOLOGICAL MARKER; CD163 ANTIGEN; DOUBLE STRANDED DNA ANTIBODY; GROWTH ARREST SPECIFIC PROTEIN 6; INTERFERON; MEMBRANE RECEPTOR; PHOSPHOLIPID ANTIBODY; PROTEIN S; PROTEIN TYROSINE KINASE; RECEPTOR; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; RO60 ANTIBODY; SM ANTIBODY; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; B LYMPHOCYTE ANTIGEN; IMMUNOGLOBULIN RECEPTOR; ONCOPROTEIN;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNITY; CHROMATIN; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; MACROPHAGE; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCYTE; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MOUSE ERYTHROCYTE RECEPTOR; PATHOLOGY;

ADULT; ANTIBODY SPECIFICITY; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; AUTOANTIBODIES; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, IMMUNOLOGIC;

EID: 84891418230     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4407     Document Type: Article

References (54)

1. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998, 41:1241-1250. 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H, 9663482.
2. Muñoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010, 6:280-289. 10.1038/nrrheum.2010.46, 20431553.
3. Shao WH, Cohen PL. Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res Ther 2011, 13:202. 10.1186/ar3535, 3157636, 21371352.
4. Wu X, Molinaro C, Johnson N, Casiano CA. Secondary necrosis is a source of proteolytically modified forms of specific intracellular autoantigens: implications for systemic autoimmunity. Arthritis Rheum 2001, 44:2642-2652. 10.1002/1529-0131(200111)44:11<2642::AID-ART444>3.0.CO;2-8, 11710720.
5. Vanden Berghe T, Vanlangenakker N, Parthoens E, Deckers W, Devos M, Festjens N, Guerin CJ, Brunk UT, Declercq W, Vandenabeele P. Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. Cell Death Differ 2010, 17:922-930. 10.1038/cdd.2009.184, 20010783.
6. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997, 390:350-351. 10.1038/37022, 9389474.
7. Xu W, Roos A, Schlagwein N, Woltman AM, Daha MR, van Kooten C. IL-10-producing macrophages preferentially clear early apoptotic cells. Blood 2006, 107:4930-4937. 10.1182/blood-2005-10-4144, 16497970.
8. McColl A, Bournazos S, Franz S, Perretti M, Morgan BP, Haslett C, Dransfield I. Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. J Immunol 2009, 183:2167-2175. 10.4049/jimmunol.0803503, 19597001.
9. Zizzo G, Hilliard BA, Monestier M, Cohen PL. Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction. J Immunol 2012, 189:3508-3520. 10.4049/jimmunol.1200662, 3465703, 22942426.
10. Alciato F, Sainaghi PP, Sola D, Castello L, Avanzi GC. TNF-α, IL-6, and IL-1 expression is inhibited by Gas6 in monocytes/macrophages. J Leukoc Biol 2010, 87:869-875. 10.1189/jlb.0909610, 20103767.
11. Camenisch TD, Koller BH, Earp HS, Matsushima GK. A novel receptor tyrosine kinase, Mer, inhibits TNF-α production and lipopolysaccharide-induced endotoxic shock. J Immunol 1999, 162:3498-3503.
12. Wallet MA, Flores RR, Wang Y, Yi Z, Kroger CJ, Mathews CE, Earp HS, Matsushima G, Wang B, Tisch R. MerTK regulates thymic selection of autoreactive T cells. Proc Natl Acad Sci U S A 2009, 106:4810-4815. 10.1073/pnas.0900683106, 2660755, 19251650.
13. Eken C, Martin PJ, Sadallah S, Treves S, Schaller M, Schifferli JA. Ectosomes released by polymorphonuclear neutrophils induce a MerTK-dependent anti-inflammatory pathway in macrophages. J Biol Chem 2010, 285:39914-39921. 10.1074/jbc.M110.126748, 3000973, 20959443.
14. Zizzo G, Cohen PL. IL-17 stimulates differentiation of human anti-inflammatory macrophages and phagocytosis of apoptotic neutrophils in response to IL-10 and glucocorticoids. J Immunol 2013, 190:5237-5246. 10.4049/jimmunol.1203017, 23596310.
15. Sharif MN, Sosic D, Rothlin CV, Kelly E, Lemke G, Olson EN, Ivashkiv LB. Twist mediates suppression of inflammation by type I IFNs and AXL. J Exp Med 2006, 203:1891-1901. 10.1084/jem.20051725, 2118370, 16831897.
16. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007, 131:1124-1136. 10.1016/j.cell.2007.10.034, 18083102.
17. Scutera S, Fraone T, Musso T, Cappello P, Rossi S, Pierobon D, Orinska Z, Paus R, Bulfone-Paus S, Giovarelli M. Survival and migration of human dendritic cells are regulated by an IFN-α-inducible AXL/Gas6 pathway. J Immunol 2009, 183:3004-3013. 10.4049/jimmunol.0804384, 19657094.
18. Wilhelm I, Nagyoszi P, Farkas AE, Couraud PO, Romero IA, Weksler B, Fazakas C, Dung NT, Bottka S, Bauer H, Bauer HC, Krizbai IA. Hyperosmotic stress induces Axl activation and cleavage in cerebral endothelial cells. J Neurochem 2008, 107:116-126. 10.1111/j.1471-4159.2008.05590.x, 18673450.
19. Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM, Graham DK. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 2007, 109:1026-1033. 1785151, 17047157.
20. Thorp E, Vaisar T, Subramanian M, Mautner L, Blobel C, Tabas I. Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase Cδ, and p38 mitogen-activated protein kinase (MAPK). J Biol Chem 2011, 286:33335-33344. 10.1074/jbc.M111.263020, 3190938, 21828049.
21. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277. 10.1002/art.1780251101, 7138600.
22. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Austin A, Bell A, Bloch DA, Corey PN, Decker JL, Esdaile J, Fries JF, Ginzler EM, Goldsmith CH, Hochberg MC, Jones JV, Riche NGHL, Liang MH, Lockshin MD, Muenz LR, Sackett DL, Schur PH. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992, 35:630-640. 10.1002/art.1780350606, 1599520.
23. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, Symmons DP, Viner N, Zoma A. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993, 86:447-458.
24. Suh CH, Hilliard B, Li S, Merrill JT, Cohen PL. TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthritis Res Ther 2010, 12:R146. 10.1186/ar3088, 2945040, 20637106.
25. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003, 100:2610-2615. 10.1073/pnas.0337679100, 151388, 12604793.
26. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006, 25:383-392. 10.1016/j.immuni.2006.08.010, 16979570.
27. Etzerodt A, Maniecki MB, Møller K, Møller HJ, Moestrup SK. Tumor necrosis factor α-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163. J Leukoc Biol 2010, 88:1201-1205. 10.1189/jlb.0410235, 20807704.
28. Wu J, Ekman C, Jönsen A, Sturfelt G, Bengtsson AA, Gottsäter A, Lindblad B, Lindqvist E, Saxne T, Dahlbäck B. Increased plasma levels of the soluble Mer tyrosine kinase receptor in systemic lupus erythematosus relate to disease activity and nephritis. Arthritis Res Ther 2011, 13:R62. 10.1186/ar3316, 3132057, 21496228.
29. Recarte-Pelz P, Tàssies D, Espinosa G, Hurtado B, Sala N, Cervera R, Reverter JC, de Frutos PG. Vitamin K-dependent proteins Gas6 and Protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activity. Arthritis Res Ther 2013, 15:R41. 10.1186/ar4199, 3672795, 23497733.
30. Nakayama W, Jinnin M, Makino K, Kajihara I, Makino T, Fukushima S, Sakai K, Inoue Y, Ihn H. CD163 expression is increased in the involved skin and sera of patients with systemic lupus erythematosus. Eur J Dermatol 2012, 22:512-517.
31. Sierra-Filardi E, Vega MA, Sánchez-Mateos P, Corbí AL, Puig-Kröger A. Heme Oxygenase-1 expression in M-CSF-polarized M2 macrophages contributes to LPS-induced IL-10 release. Immunobiology 2010, 215:788-795. 10.1016/j.imbio.2010.05.020, 20580464.
32. Nielsen MJ, Møller HJ, Moestrup SK. Hemoglobin and heme scavenger receptors. Antioxid Redox Signal 2010, 12:261-273. 10.1089/ars.2009.2792, 19659436.
33. Anwar A, Keating AK, Joung D, Sather S, Kim GK, Sawczyn KK, Brandão L, Henson PM, Graham DK. Mer tyrosine kinase (MerTK) promotes macrophage survival following exposure to oxidative stress. J Leukoc Biol 2009, 86:73-79. 10.1189/jlb.0608334, 2704622, 19386698.
34. Li Y, Gerbod-Giannone MC, Seitz H, Cui D, Thorp E, Tall AR, Matsushima GK, Tabas I. Cholesterol-induced apoptotic macrophages elicit an inflammatory response in phagocytes, which is partially attenuated by the Mer receptor. J Biol Chem 2006, 281:6707-6717. 10.1074/jbc.M510579200, 16380374.
35. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 2001, 293:306-311. 10.1126/science.1061663, 11452127.
36. Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, Roubey RA, Earp HS, Matsushima G, Reap EA. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 2002, 196:135-140. 10.1084/jem.20012094, 2194017, 12093878.
37. Cheong HS, Lee SO, Choi CB, Sung YK, Shin HD, Bae SC. MerTK polymorphisms associated with risk of haematological disorders among Korean SLE patients. Rheumatology (Oxford) 2007, 46:209-214.
38. Wu CS, Hu CY, Chan CJ, Chang SK, Hsu PN. Genetic polymorphism of the growth arrest-specific 6 gene is associated with cutaneous vasculitis in Taiwanese patients with systemic lupus erythematosus. Clin Rheumatol 2012, 31:1443-1448. 10.1007/s10067-012-2027-z, 22763415.
39. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 2005, 11:867-874. 10.1038/nm1275, 16041383.
40. Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol 2011, 32:380-387. 10.1016/j.it.2011.05.005, 21752713.
41. Garbin U, Baggio E, Stranieri C, Pasini A, Manfro S, Mozzini C, Vallerio P, Lipari G, Merigo F, Guidi G, Cominacini L, Fratta PA. Expansion of necrotic core and shedding of MerTK receptor in human carotid plaques: a role for oxidized polyunsaturated fatty acids?. Cardiovasc Res 2013, 97:125-133. 10.1093/cvr/cvs301, 22997156.
42. Timmermann M, Högger P. Oxidative stress and 8-iso-ProStaglandin F(2alpha) induce ectodomain shedding of CD163 and release of tumor necrosis factor-alpha from human monocytes. Free Radic Biol Med 2005, 39:98-107. 10.1016/j.freeradbiomed.2005.02.031, 15925282.
43. Rovida E, Paccagnini A, Del Rosso M, Peschon J, Dello SP. TNF-alpha-converting enzyme cleaves the macrophage colony-stimulating factor receptor in macrophages undergoing activation. J Immunol 2001, 166:1583-1589.
44. Murumkar PR, DasGupta S, Chandani SR, Giridhar R, Yadav MR. Novel TACE inhibitors in drug discovery: a review of patented compounds. Expert Opin Ther Pat 2010, 20:31-57. 10.1517/13543770903465157, 20021284.
45. Ekman C, Stenhoff J, Dahlbäck B. Gas6 is complexed to the soluble tyrosine kinase receptor AXL in human blood. J Thromb Haemost 2010, 8:838-844. 10.1111/j.1538-7836.2010.03752.x, 20088931.
46. Ekman C, Jönsen A, Sturfelt G, Bengtsson AA, Dahlbäck B. Plasma concentrations of Gas6 and sAXL correlate with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2011, 50:1064-1069. 10.1093/rheumatology/keq459, 3093930, 21278074.
47. Ekman C, Gottsäter A, Lindblad B, Dahlbäck B. Plasma concentrations of Gas6 and soluble AXL correlate with disease and predict mortality in patients with critical limb ischemia. Clin Biochem 2010, 43:873-876. 10.1016/j.clinbiochem.2010.04.006, 20417630.
48. Reed JH, Jackson MW, Gordon TP. B cell apotopes of the 60-kDa Ro/SSA and La/SSB autoantigens. J Autoimmun 2008, 31:263-267. 10.1016/j.jaut.2008.04.008, 18511235.
49. Dugar M, Cox S, Limaye V, Gordon TP, Roberts-Thomson PJ. Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. Postgrad Med J 2010, 86:79-82. 10.1136/pgmj.2009.089656, 20145055.
50. Hafizi S, Dahlbäck B. Gas6 and protein S. Vitamin K-dependent ligands for the AXL receptor tyrosine kinase subfamily. FEBS J 2006, 273:5231-5244. 10.1111/j.1742-4658.2006.05529.x, 17064312.
51. Uehara H, Shacter E. Auto-oxidation and oligomerization of protein S on the apoptotic cell surface is required for Mer tyrosine kinase-mediated phagocytosis of apoptotic cells. J Immunol 2008, 180:2522-2530.
52. Dahlbäck B, Wiedmer T, Sims PJ. Binding of anticoagulant vitamin K-dependent protein S to platelet-derived microparticles. Biochemistry 1992, 31:12769-12777. 10.1021/bi00166a009, 1463747.
53. Sellam J, Proulle V, Jüngel A, Ittah M, Miceli Richard C, Gottenberg JE, Toti F, Benessiano J, Gay S, Freyssinet JM, Mariette X. Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res Ther 2009, 11:R156. 10.1186/ar2833, 2787287, 19832990.
54. Gris JC, Toulon P, Brun S, Maugard C, Sarlat C, Schved JF, Berlan J. The relationship between plasma microparticles, protein S and anticardiolipin antibodies in patients with human immunodeficiency virus infection. Thromb Haemost 1996, 76:38-45.